HOX7 Antibody

What is HOXA7 and why are HOXA7 antibodies important in cancer research?

HOXA7 is a homeobox transcription factor that plays crucial roles in development and is aberrantly expressed in various cancers. HOXA7 antibodies are essential tools for understanding the role of this protein in tumorigenesis.

In ovarian cancer, HOXA7 expression is detected in tumors exhibiting müllerian-like features and correlates with the generation of anti-HOXA7 antibodies by patients, while being absent from normal ovarian surface epithelium . In liver cancer, HOXA7 promotes metastasis by activating Snail, with higher expression levels associated with poorer prognosis .

Antibodies against HOXA7 enable researchers to:

• Detect and quantify HOXA7 expression in various tissues and cell lines

• Study subcellular localization through immunofluorescence

• Investigate protein-protein and protein-DNA interactions

• Evaluate HOXA7 as a potential biomarker for cancer diagnosis and prognosis

What experimental techniques can utilize HOXA7 antibodies?

HOXA7 antibodies can be employed in multiple experimental techniques:

The detection of HOXA7 by Western blotting typically reveals a band of approximately 25 kDa , though the observed molecular weight may vary depending on post-translational modifications.

How should researchers validate the specificity of HOX7 antibodies?

Validation of HOX7 antibodies is critical for ensuring reliable experimental results. Recommended validation approaches include:

• Positive and negative control samples: Use cell lines with known HOXA7/HOXB7 expression levels (e.g., HepG2 cells for HOXA7 ) and compare with knockout or knockdown samples.

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide before application to verify signal specificity.

• Multiple antibody comparison: Use antibodies from different sources or those targeting different epitopes of HOXA7.

• Correlate protein with mRNA levels: Compare antibody detection with RT-PCR results to confirm expression patterns .

• Recombinant protein standards: Use purified recombinant HOXA7 as a positive control in Western blots .

How can researchers use HOXA7 antibodies to investigate its role in cancer metastasis?

HOXA7 has been implicated in promoting metastasis, particularly in liver cancer . To investigate this function:

• Metastatic vs. non-metastatic comparison: Use HOXA7 antibodies in immunohistochemistry to compare expression between primary tumors and metastatic lesions. Research shows HOXA7 levels are increased in metastatic liver cancer compared to non-metastatic samples .

• ChIP-sequencing approach: Employ HOXA7 antibodies in ChIP experiments to identify direct transcriptional targets:

  • HOXA7 has been shown to bind the Snail promoter region (-2400 to -2150), directly activating its transcription .

  • Use appropriate controls including IgG and input chromatin samples.

  • Optimize sonication conditions to generate 200-500bp DNA fragments.

• In vivo metastasis models: Use HOXA7 antibodies to validate knockdown or overexpression in cells before injection into mouse models, then perform immunohistochemical analysis of resulting tumors and metastases .

What methodological considerations are important for chromatin immunoprecipitation with HOXA7 antibodies?

Chromatin immunoprecipitation (ChIP) with HOXA7 antibodies requires careful optimization:

• Antibody selection: Use ChIP-validated antibodies. For example, Cell Signaling Technology's HOXB7 (E3H4S) Rabbit mAb has been validated for ChIP at a recommended dilution of 1:50 .

• Crosslinking optimization:

  • For detecting direct DNA binding: 1% formaldehyde for 10 minutes at room temperature

  • For protein complexes: Consider dual crosslinking with DSG followed by formaldehyde

• Sonication parameters: Optimize sonication conditions to generate DNA fragments of 200-500bp, suitable for identifying binding regions.

• Controls:

  • Input chromatin (non-immunoprecipitated)

  • IgG negative control

  • Positive control (antibody against a known transcription factor)

• Target validation: Confirm binding sites with quantitative PCR targeting specific promoter regions. Research has demonstrated HOXA7 binding to the Snail promoter region (-2400 to -2150) .

• Data analysis: Use appropriate statistical methods to determine significant binding events compared to background.

How can HOXA7 antibodies help distinguish between normal and pathological expression patterns?

HOXA7 shows distinct expression patterns in normal versus diseased tissues, making antibody-based detection valuable for pathological studies:

• Ovarian cancer application:

  • HOXA7 is absent in normal ovarian surface epithelium

  • HOXA7 is expressed in müllerian-like epithelium lining inclusion cysts in normal ovaries

  • HOXA7 expression is detected in ovarian tumors with müllerian-like features

  • Expression correlates with serological reactivity to HOXA7 in patients

• Liver cancer application:

  • Higher HOXA7 expression correlates with poorer prognosis

  • HOXA7 promotes proliferation, migration, and invasion in vitro

  • HOXA7 enhances tumor growth and metastasis in vivo

• Tissue microarray analysis: Use HOXA7 antibodies on tissue microarrays containing multiple patient samples to correlate expression with clinicopathological features.

• Quantitative immunohistochemistry: Employ digital image analysis to quantify HOXA7 expression levels and subcellular localization patterns.

What are common issues in HOXA7/HOXB7 antibody applications and how can they be addressed?

How should researchers interpret HOXA7 immunostaining patterns in complex tissues?

Interpretation of HOXA7 immunostaining requires careful consideration of:

How can single-cell approaches utilizing HOXA7 antibodies advance our understanding of tumor heterogeneity?

Emerging single-cell technologies with HOXA7 antibodies offer new insights into tumor heterogeneity:

• Single-cell proteomics:

  • Mass cytometry (CyTOF) with metal-conjugated HOXA7 antibodies enables simultaneous detection of multiple proteins at single-cell resolution

  • Spatial proteomics techniques allow visualization of HOXA7 in the context of the tumor microenvironment

• Multi-omics integration:

  • Correlate HOXA7 protein expression with single-cell transcriptomics

  • Identify cellular subpopulations with distinct HOXA7 expression patterns and functional states

• Lineage tracing:

  • Use HOXA7 antibodies to characterize cancer stem cells and their progeny

  • Track changes in HOXA7 expression during tumor progression and metastasis

What is the potential of HOXA7 antibodies for the development of diagnostic and therapeutic applications?

Research indicates several promising applications for HOXA7 antibodies beyond basic research:

• Serum diagnostics:

  • Anti-HOXA7 antibodies have been detected in the serum of patients with ovarian tumors but not in healthy controls (P < 0.0001)

  • Approximately 67% of patients with moderately differentiated serous carcinomas generate anti-HOXA7 antibodies

  • 68% of patients with benign serous cystadenomas generate anti-HOXA7 antibodies

• Therapeutic targeting:

  • HOXA7's role in promoting metastasis makes it a potential therapeutic target

  • Antibody-drug conjugates could potentially deliver cytotoxic agents to HOXA7-expressing cells

  • Antibody-based redirection of universal CAR-T cells could target HOXA7-expressing tumor cells

• Prognostic stratification:

  • HOXA7 expression correlates with prognosis in liver cancer patients

  • Antibody-based detection could help stratify patients for personalized treatment approaches

How can researchers study the relationship between HOXA7 and adipogenesis using HOX7 antibodies?

While not directly related to HOXA7/HOXB7, research on HOX-7 (a dietary formula) reveals anti-obesity effects that may share molecular mechanisms with HOXA genes:

• Comparative analysis:

  • Study the effects of HOX-7 dietary formula on adipogenesis

  • Investigate whether HOXA7/HOXB7 expression changes in response to HOX-7 treatment

  • Explore potential overlapping molecular pathways

• Adipogenesis markers:

  • Examine how HOXA7 affects expression of key adipogenic transcription factors (PPARγ, C/EBPα, SREBP1c)

  • Compare with the effects of HOX-7 dietary formula on these same factors

• Functional studies:

  • Use HOXA7 antibodies to confirm knockdown or overexpression in adipocyte models

  • Investigate effects on adipocyte differentiation and lipid accumulation

  • Compare with the known effects of HOX-7 dietary formula